RxDoctor Payments Data

Gregory Campbell, MD

Pulmonary Disease · Asheville, NCNPI 1528048949

Payments from drug & device makers

$817in general payments, 2019–2025

Across 47 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$179
  • Grifols USA, LLC$120
  • Boehringer Ingelheim$84
  • Sunovion Pharmaceuticals Inc.$83
  • AstraZeneca$79
  • Insmed, Inc.$64
  • plus $209 from 9 others

What the payments were for

  • Food & beverage$78196%
  • Education$364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$817 in reported general payments places this provider in the 40th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,708
Medicare patients
447
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate18$233,906
Trelegy ElliptaFluticasone/Umeclidin/Vilanter312$220,238
NucalaMepolizumab13$143,864
Spiriva RespimatTiotropium Bromide81$58,805
Breo ElliptaFluticasone/Vilanterol110$54,726
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$38,134
SymbicortBudesonide/Formoterol Fumarate67$20,402
Bevespi AerosphereGlycopyrrolate/Formoterol Fum18$13,613
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$12,875
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$12,584
Arnuity ElliptaFluticasone Furoate28$10,817
Advair HfaFluticasone Propion/Salmeterol23$10,317
Combivent RespimatIpratropium/Albuterol Sulfate19$9,597
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate50$9,260
EliquisApixaban14$7,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$38$446,637499 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$84$314,892141 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$79$72,150144 claims
PfizerEliquis$24$7,62214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →